Free Trial

INmune Bio (INMB) Stock Forecast & Price Target

INmune Bio logo
$2.08 -0.06 (-2.80%)
Closing price 10/3/2025 04:00 PM Eastern
Extended Trading
$2.07 -0.01 (-0.43%)
As of 10/3/2025 07:46 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

INmune Bio - Analysts' Recommendations and Stock Price Forecast (2025)

Consensus Rating

Sell
2
Hold
2
Buy
4

Based on 8 Wall Street analysts who have issued ratings for INmune Bio in the last 12 months, the stock has a consensus rating of "Hold." Out of the 8 analysts, 2 have given a sell rating, 2 have given a hold rating, 3 have given a buy rating, and 1 has given a strong buy rating for INMB.

Consensus Price Target

$18.50
789.42% Upside
According to the 8 analysts' twelve-month price targets for INmune Bio, the average price target is $18.50. The highest price target for INMB is $23.00, while the lowest price target for INMB is $8.00. The average price target represents a forecasted upside of 789.42% from the current price of $2.08.
MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
Get the Latest News and Ratings for INMB and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for INmune Bio and its competitors.

Sign Up
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

INMB Analyst Ratings Over Time

TypeCurrent Forecast
10/4/24 to 10/4/25
1 Month Ago
9/4/24 to 9/4/25
3 Months Ago
7/6/24 to 7/6/25
1 Year Ago
10/5/23 to 10/4/24
Strong Buy
1 Strong Buy rating(s)
1 Strong Buy rating(s)
1 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
3 Buy rating(s)
3 Buy rating(s)
3 Buy rating(s)
2 Buy rating(s)
Hold
2 Hold rating(s)
2 Hold rating(s)
2 Hold rating(s)
0 Hold rating(s)
Sell
2 Sell rating(s)
1 Sell rating(s)
1 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$18.50$18.40$18.40$20.00
Forecasted Upside789.42% Upside858.33% Upside606.33% Upside266.30% Upside
Consensus RatingHoldModerate BuyModerate BuyBuy

INMB Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

INMB Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

INmune Bio Stock vs. The Competition

TypeINmune BioMedical CompaniesS&P 500
Consensus Rating Score
2.38
2.33
2.51
Consensus RatingHoldHoldModerate Buy
Predicted Upside789.42% Upside1,395.18% Upside10.50% Upside
News Sentiment Rating
Neutral News

See Recent INMB News
Positive News
Positive News
DateBrokerageAnalystActionRatingPrice TargetReport Date
Upside/Downside
Details
9/27/2025Weiss Ratings
0 of 5 stars
 Reiterated RatingSell (E+)
7/2/2025Maxim Group
1 of 5 stars
Jason McCarthy
Jason McCarthy
1 of 5 stars
Lower TargetBuy$30.00 ➝ $8.00+241.59%
7/1/2025BTIG Research
2 of 5 stars
Thomas Shrader
Thomas Shrader
Not Rated
Reiterated RatingBuyNeutral
7/1/2025Scotiabank
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSector OutperformSector Underperform
6/30/2025Raymond James Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeModerate BuyHold
1/28/2025RODMAN&RENSHAW
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong-Buy
1/28/2025Rodman & Renshaw
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Initiated CoverageBuy$23.00+190.77%
10/21/2024Alliance Global Partners
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$20.00+291.39%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 10:56 AM ET.


INMB Forecast - Frequently Asked Questions

According to the research reports of 8 Wall Street equities research analysts, the average twelve-month stock price forecast for INmune Bio is $18.50, with a high forecast of $23.00 and a low forecast of $8.00.

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for INmune Bio in the last year. There are currently 2 sell ratings, 2 hold ratings, 3 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" INMB shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in INMB, but not buy additional shares or sell existing shares.

According to analysts, INmune Bio's stock has a predicted upside of 789.42% based on their 12-month stock forecasts.

INmune Bio has been rated by research analysts at Weiss Ratings in the past 90 days.

Analysts like INmune Bio more than other "medical" companies. The consensus rating score for INmune Bio is 2.38 while the average consensus rating score for "medical" companies is 2.33. Learn more on how INMB compares to other companies.


This page (NASDAQ:INMB) was last updated on 10/4/2025 by MarketBeat.com Staff
From Our Partners